MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance
UK regulator to allow three- and five-year transitions for CE-marked devices and diagnostics
26 June saw the release finally of the UK government’s official response to the MHRA’s 2021 consultation on its post-Brexit medical devices regulatory framework. The considered response, held up by political and internal timing issues, represents an implementation plan for reform of the system. Crucially it allows industry extra compliance time.
You may also be interested in...
The role and purpose of medical device regulation is now better understood than at any time in its history, and regulators are no longer seen as gatekeepers preventing business from happening. Graeme Tunbridge, formerly at the MHRA and now a senior VP at leading conformity assessment body BSI, is a champion of the climate of inclusivity.
The current turmoil at the heart of the UK government is the last thing the medtech industry needs right now as it awaits publication of the new, post-Brexit UK medtech regulations.
Teething troubles including staffing issues and a hold-up in the progress of the post-Brexit medical devices statutory instruments have beset the UK MHRA as it transforms to a new lifecycle-based regulatory agency that puts primacy on patient safety. But there is much to celebrate, says chief executive June Raine.